Jasperate

Jasperate

Early Stage

Reduce Pain and Suffering Caused by Trigger Finger

Reduce Pain and Suffering Caused by Trigger Finger

Overview

Raised this Round: Raised: $100,000

Total Commitments ($USD)

Platform

StartEngine

Start Date

10/01/2017

Close Date

12/28/2017

Min. Goal
$10,000
Max. Goal
$100,000
Min. Investment

$100

Security Type

Equity - Common

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share

$1.00

Pre-Money Valuation

$500,000

Year Founded

2017

Industry

Healthcare & Pharmaceuticals

Tech Sector

Location

Lisle, Illinois

Needles. Nothing like a baby screaming at a doctor’s office to be reminded of how much you don’t like shots. Sometimes though, they’re unavoidable. That’s especially true for people with trigger finger. Trigger finger is when a tendon in finger becomes inflamed leading to stiffness, a popping or clicking sensation, or the finger becoming locked when bent. Relief often only comes through an (often painful) injection. Shudder, shudder.

That’s where (insert drumroll here please) J-needle comes into play. Using a patent-pending curved needle, the J-needle doesn’t directly pierce the tendon of the inflamed finger. Instead, it enters at an angle, saving both the patient and doctor time, improving accuracy of the medical procedure, and providing the patient with immediate relief. In fact, Jasperate claims that, with the J-needle, doctors can double the amount of trigger fingers treated in a given session. Bam!

Considering that there are 200,000 new cases of trigger finger reported each year, that’s a pretty big deal. Ten percent of diabetics get it, 2-3% of people with it get it randomly. With the population aging and becoming more obese, those numbers (unfortunately) are going to keep rising. In addition to trigger finger, the J-needle can also be used to treat for joint pain, in plastic surgery, neurology, anesthesiology, eye injections...the list goes on. It’s like the superhero of needles.

Founder and Chief Medical Advisor, Dr. Stephen Soloway, has been a doctor for the past 30 years and has earned Top Doctor Awards every year since 2003. The J-needle came out of his experience working with traditional needles and seeing that a change needed to happen. CEO David Weksel and COO Charles Brunner both have extensive leadership experience at companies such as Accenture and SharkNinja, and none of the principal employees will take a salary until revenue is recognized.

J-needles seem to be the only needle of its kind, and with more waistlines expanding and more fingers locking, there is definitely a need for it. Jasperate just might be the pinprick you’ve been looking for to take a stab at a medical investment.
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Jasperate on Start Engine
Platform: StartEngine
Security Type: Equity - Common
Valuation: $500,000
Price per Share: $1.00

Follow company

Follow Jasperate on Start Engine

Buy Jasperate's Deal Report

Warning: according to the close date for this deal, Jasperate may no longer be accepting investments.

Jasperate Deal Report

Get KingsCrowd’s comprehensive report on Jasperate including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Jasperate is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Jasperate deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge